The aim of NBCS is to investigate lifestyle factors and genetic factors in relation to the risk of bladder cancer, the course of the disease, and the effect of therapy. The influence of specific characteristics of the bladder tumor itself on the course and effect of therapy is also being studied. The ambition of NBCS is to be able to determine which people are at high risk of developing a bladder tumor and to be able to personalize the treatment of patients with a bladder tumor even better to the individual patient. NBCS consists of questionnaire data, additional information from medical files and existing national health registration systems (cancer registries, registries of death certificates and pathology archives) and biomaterial (DNA, whole blood and tumor tissue).
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Dutch-Nordic Alliance for Precision Cancer Medicine launched26 November 2021
The Nordic countries (Denmark, Sweden, Norway, and Finland) are together setting up national clinical precision cancer trials modelled on the very successful DRUP trial in the Netherlands.read more
New Automated PBMC isolation method introduced in LMI.21 September 2021
The Radboud Biobank (RB) and the laboratory of Medical Immunology (LMI) are making plans to replace the density gradient centrifugation method with a new automated PBMC isolation method, the AutoMACS Pro Separator.read more
Lysine Metabolism sub-biobank21 September 2021
Hereditary metabolic disorders form a large group of more than 1,400 rare disorders in which an error in the DNA causes abnormalities in the process in which proteins, fats and carbohydrates are converted into smaller building materials and energy.read more